The U.S. Food and Drug Administration approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer’s drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.

According to data published in The New England Journal of Medicine, a Phase I trial of Moderna’s mRNA vaccine against SARS-CoV-2 demonstrated promising safety and immune response in all patients involved in the study.

The U.S. Supreme Court ruled in favor of health insurers seeking $12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans.

CVS Health Corp.’s pharmacy benefit management (PBM) unit is launching a new program under which employers and insurers will be able to offer diabetes drugs, including insulin, at no out-of-pocket costs to their members.

Civica Rx and 18 independent Blue Cross and Blue Shield (BCBS) companies formed a new subsidiary dedicated to lowering the cost of select generic drugs.

Walgreens Boots Alliance Inc.’s quarterly profit missed Wall Street estimates, hit by lower payments from insurers on drugs sold at the company’s U.S. pharmacies, knocking back the pharmacy store chain’s shares and those of rival CVS Health Corp.

Cigna Corp. agreed to sell the health insurer’s disability and accidental death insurance unit for company employees to New York Life Insurance Co. in a $6.3 billion deal.

CVS Health Corp. said the company will make it easier for patients with advanced cancer enrolled in some Aetna insurance plans to receive broad genetic gene sequencing tests that can help identify the best drug or treatment for them.

A U.S. government watchdog is raising fresh concerns that health insurers are exaggerating how sick Medicare patients are, receiving billions of dollars in improper payments as a result.

U.S. Supreme Court justices appeared sympathetic to claims made by health insurers seeking $12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans.